Chen L, Jiang YZ, Wu SY, Wu J, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial. Clin Cancer Res 2022 Mar 3. pii: 681997. doi: 10.1158/1078-0432.CCR-21-4313.
PMID: 35247906